Y. Xie

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.

Xin-jun Liu, D. Grigoriadis, K. Wilcoxen, 2004, Journal of medicinal chemistry.

Identification of novel series of human CCR1 antagonists.

J. Li, I. Sircar, Kui Xu, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.

D. Grigoriadis, K. Wilcoxen, T. Webb, 2003, Bioorganic & medicinal chemistry letters.

Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.

Nanxin Li, J. Shaffer, S. Kasibhatla, 2020, ACS medicinal chemistry letters.

Rapid microscale synthesis: Solution phase parallel synthesis of a library of piperazines and piperidines using a water soluble base

J. Mccarthy, J. Whitten, Y. Xie, 1998 .

Hypercrosslinking Polymers Fabricated from Divinyl Benzene via Friedel-Crafts Addition Polymerization

Zhiyong Chen, Zhengyu Duan, Y. Xie, 2022, Chinese Journal of Polymer Science.

Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists

C. Chen, D. Grigoriadis, T. Webb, 1997 .

Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-d]pyrimidine RET Inhibitors.

Nanxin Li, J. Shaffer, S. Kasibhatla, 2021, ACS medicinal chemistry letters.